Objective To investigate the expression changes of GLDN(Gliomedin)in glio-blastoma(GBM)tissues and cell lines,and its impact on patient prognosis.Methods By conduc-ting further mining and analysis of sequencing data from previously published studies on glioblas-toma multiforme(GBM)drug resistance within our research group,we downloaded the GSE113510 mRNA sequencing data from the international GEO database,GLDN was identified as the gene with the most significant differential expression.The expression differences of GLDN be-tween primary and recurrent GBM tissues were analyzed using the CGGA database.GLDN mR-NA levels in GBM cell lines were measured by quantitative real-time PCR,and protein levels were detected by Western blotting.Survival analysis using the CGGA and TCGA databases was conducted to examine the relationship between GLDN expression and patient prognosis.Results Analysis of the GSE113510 dataset revealed that GLDN exhibited the most significant differential expression in drug-resistant GBM cell lines.GLDN expression was significantly higher in recur-rent GBM tissues compared to primary GBM tissues(P＜0.05).Additionally,GLDN expression was markedly elevated in drug-resistant cell lines 229R,251R,and HG7R compared to their non-resistant counterparts(P＜0.05).Survival analysis showed that high GLDN expression was as-sociated with poorer patient prognosis,with a significantly shorter survival time.Conclusion GLDN is highly expressed in glioblastoma and is closely associated with drug resistance and poor prognosis.It may serve as a potential therapeutic target in GBM treatment.
NETL
NSTL
万方数据
